Introduction
============

Surgical liver resection is the most effective treatment for colorectal liver metastases (CRLM) and is currently the only potentially curative therapeutic option ([@b1-mco-0-0-1623],[@b2-mco-0-0-1623]). Previously, preoperative chemotherapy was demonstrated to improve prognosis and increase conversion to resectability in patients with CRLM ([@b3-mco-0-0-1623]--[@b5-mco-0-0-1623]). However, preoperative chemotherapy is not always effective and the disease may progress ([@b6-mco-0-0-1623]). Therefore, it may be beneficial to personalize treatment based on the individual molecular characteristics of the tumor. Identification of predictive markers for the response to preoperative chemotherapy may help to ensure prompt selection of effective drugs for each patient and to avoid unnecessary administration of ineffective or even harmful drugs. Furthermore, the reduction in treatment costs would have economic benefits.

There are currently no molecular markers of chemosensitivity to predict the response of CRLM to 5-fluorouracil (5-FU)- and oxaliplatin-based treatment regimens, such as FOLFOX (5-FU, folinic acid and oxaliplatin) and XELOX (capecitabine and oxaliplatin). Thymidylate synthase (TS) and excision repair cross-complementation group 1 (ERCC1) have been shown to be useful predictors of the response to 5-FU- and oxaliplatin-based chemotherapy in colorectal cancer (CRC) ([@b7-mco-0-0-1623]--[@b12-mco-0-0-1623]). However, little is known on the direct association between TS and ERCC1 expression as detected by immunohistochemistry (IHC) of tumor tissues and the response to 5-FU- and oxaliplatin-based preoperative chemotherapy for CRLM. Furthermore, it is not known whether TS and ERCC1 expression levels in the primary lesions and CRLM are associated.

The aim of the present study was to evaluate TS and ERCC1 expression in primary lesions and CRLM as predictive markers for the response to preoperative chemotherapy according to both histological \[tumor regression grade (TRG)\] and radiological \[Response Evaluation Criteria in Solid Tumors (RECIST)\] assessments. Identification of predictive markers for response to chemotherapy may help identify the CRLM patients who would most benefit from preoperative chemotherapy.

Patients and methods
====================

### Patients

The present study included 24 consecutive patients with CRLM who were treated with 5-FU- and oxaliplatin-based preoperative chemotherapy between January 2007 and February 2016. Selection of the chemotherapy regimen was not randomized, but rather determined by the clinician\'s preference. Medical records were reviewed and clinical data were retrospectively obtained. This study was conducted in compliance with the Declaration of Helsinki and in accordance with guidelines approved by the Institutional Research Board of Kindai University Nara Hospital (no. 364).

### Immunohistochemistry

A total of 23 paired samples of formalin-fixed, paraffin-embedded sections from primary tumors and CRLM and 1 unpaired CRLM section were deparaffinized with xylene, rehydrated with a graded series of aqueous ethanol solutions, and then stained as briefly described herein. For antigen retrieval, the sections were placed in citrate buffer (pH 6.0) and autoclaved at 121°C for 10 min. Endogenous peroxidase activity was blocked by incubation of sections with a 3% hydrogen peroxide solution at room temperature for 15 min, followed by rinsing with 0.05 M phosphate-buffered saline (PBS) and blocking with Blocking One solution (Nacalai Tesque, Kyoto, Japan) at room temperature for 10 min. The sections were then incubated with rabbit anti-TS monoclonal antibody (1:500, clone TS106, Dako, Tokyo, Japan) or mouse anti-ERCC1 monoclonal antibody (1:250, clone 8F1, Abcam, Cambridge, UK) overnight at 4°C. Following washing with PBS, the sections were incubated with universal immuno-peroxidase polymer (N-Histofine Simple Stain MAX, Nichirei Co., Tokyo, Japan) at room temperature for 30 min. After washing again with PBS, peroxidase activity was detected by incubation with 3,3′-diaminobenzidine tetrahydrochloride (DAB; Merck KGaA, Darmstadt, Germany) at room temperature for 5 min. The sections were washed again with PBS, and cell nuclei were stained with Mayer\'s hematoxylin at room temperature for 1 min. IHC qualitative scoring was performed using the ASCO/CAP criteria ([@b13-mco-0-0-1623]), i.e., 10% of cells with nuclear staining was considered as a positive staining reaction for TS and ERCC1 ([Fig. 1](#f1-mco-0-0-1623){ref-type="fig"}). The slides were examined independently by two pathologists blinded to the clinical data.

### Imaging assessment

RECIST 1.1-based evaluation of the effect of preoperative chemotherapy was assessed by experienced gastroenterological surgeons using computed tomography or magnetic resonance imaging ([@b14-mco-0-0-1623],[@b15-mco-0-0-1623]). The criteria of the Japanese Society for Cancer of the Colon and Rectum (JSCCR) were used for grading liver metastasis. This JSCCR staging system is based on the number of liver metastases as follows: H1, ≤4 metastatic tumors and the largest hepatic tumor sized ≤5 cm; H2, except H1 and H3; H3, ≥5 metastatic tumors and the largest hepatic tumor sized \>5 cm ([@b16-mco-0-0-1623]).

### Histological assessment

Two pathologists blinded to the patient\'s clinical information reviewed all histological specimens. Tumor and node staging for all resected specimens was conducted according to the 7th American Joint Committee on Cancer TNM staging manual ([@b17-mco-0-0-1623]). The TRG method was used to characterize the tumor response ([@b18-mco-0-0-1623]) based on tumor viability and the extent of fibrosis and inflammation, and TRG classes were defined as follows: TRG 1, complete regression with no residual tumor; TRG 2, presence of rare residual cancer cells; TRG 3, presence of larger numbers of residual cancer cells with predominant fibrosis; TRG 4, residual cancer outgrowing the fibrosis; and TRG 5, absence of regressive changes.

### Statistical analysis

Statistical analysis was performed using JMP Pro^®^ software, version 11 (SAS Institute, Cary, NC, USA). Continuous data are reported as median and range unless otherwise specified. Categorical data are presented as frequency and percentage. Comparison of continuous variables was performed using the Wilcoxon\'s rank-sum test. The Fisher\'s exact test was used for comparison of categorical variables as appropriate. Statistical significance was defined as P\<0.05.

Results
=======

### Patient characteristics

The patient characteristics are summarized in [Table I](#tI-mco-0-0-1623){ref-type="table"}. A total of 24 patients (8 women and 16 men) aged 39--78 years (median, 64 years) were analyzed in this study. A primary lesion specimen was missing for 1 patient who underwent surgery at another hospital. A total of 9 patients had rectal cancer and 15 patients had colon cancer. The chemotherapy regimens included modified FOLFOX6 (21 cases) and XELOX (3 cases). The median number of chemotherapy cycles was 6 (range, 3--56). Molecular-targeted drugs were administered to 20 patients: 8 patients received panitumumab, 1 received cetuximab, and 11 received bevacizumab. As regards the response to preoperative chemotherapy evaluated according to TRG, 2 patients were classified as TRG1, 13 as TRG2, 4 as TRG3, 4 as TRG4 and 1 as TRG5. As regards the response evaluated according to RECIST, 2 patients had progressive disease (PD), 5 had stable disease (SD), and 17 exhibited a partial response (PR). No patients achieved complete response (CR). Other clinical and histological data are provided in [Table I](#tI-mco-0-0-1623){ref-type="table"}.

### Correlation between TRG and RECIST assessments

We analyzed the association between the response assessed by TRG and RECIST. Patients classified as TRG1-3 were considered to be responders, while those classified as TRG4-5 were considered to be non-responders ([@b18-mco-0-0-1623]--[@b21-mco-0-0-1623]). Based on this classification, 19 patients were assigned to the responder group (TRG 1--3) and 5 to the non-responder group (TRG 4--5). Similarly, patients were assigned to two groups based on RECIST criteria: responders (PR, n=17) and non-responders (SD and PD, n=7) ([@b22-mco-0-0-1623]). The analysis identified a significant association between the response of CRLM patients to preoperative chemotherapy assessed by TRG and RECIST (P=0.0005; [Table II](#tII-mco-0-0-1623){ref-type="table"}).

### Response to preoperative chemotherapy based on RECIST

The clinicopathological data for patients in the RECIST responder (PR) and non-responder (SD + PD) groups are summarized in [Table III](#tIII-mco-0-0-1623){ref-type="table"}. The response based on RECIST was significantly associated with TS expression in the primary tumor and with the size of metastases prior to chemotherapy (P=0.0272 and P=0.0454, respectively). Other factors were not found to be significantly associated with RESICT.

### Response to preoperative chemotherapy based on TRG

The clinicopathological data for patients in the TRG responder (TRG-3) and non-responder (TRG4-5) groups are summarized in [Table IV](#tIV-mco-0-0-1623){ref-type="table"}. The response based on TRG was significantly associated with TS expression in the primary tumor (P=0.0137). Other factors were not found to be significantly associated with TRG class.

### Correlation between TS and ERCC1 expression in the primary lesion and CRCLM

As shown in [Table V](#tV-mco-0-0-1623){ref-type="table"}, no correlation was detected between TS expression in the primary lesion and that in the matched liver metastases (P=0.371). There was also no correlation detected between ERCC1 expression in the primary lesion and that in the matched liver metastasis (P=1.00).

Discussion
==========

The main methods used to assess the response of CRLM to chemotherapy include radiological and pathological grading systems ([@b19-mco-0-0-1623],[@b23-mco-0-0-1623]). In radiological assessment, the effect of chemotherapy is usually evaluated on radiographic scans according to the RECIST scoring system. Recently, Rubbia *et al* published a novel grading system, TRG, which assesses prognosis based on the pathological response to chemotherapy ([@b18-mco-0-0-1623]). In the present study, we evaluated the expression of TS and ERCC1 in the primary colorectal lesion and CRLM to determine their potential as predictive markers of the response of CRLM to preoperative chemotherapy as assessed by both the TRG and RECIST methods.

The correlation between the TRG and RECIST results were first evaluated for the 24-patient cohort in the present study and observed a significant association between the two assessment tools. A previous study demonstrated that RECIST was significantly associated with the percentage of residual tumor cells in patients treated with preoperative chemotherapy for CRLM ([@b24-mco-0-0-1623]). In that study, the authors scored the pathological response semi-quantitatively (percentage of residual tumor cells relative to the total tumor surface area) and, although our study used a slightly different method of pathological assessment, our results are consistent with the findings of Chun *et al*, confirming that radiological assessment based on RECIST was significantly associated with the pathological assessment ([@b24-mco-0-0-1623]).

Fluoropyrimidines, particularly 5-FU, have been the mainstay of systemic treatment of metastatic CRC for \>50 years. The major mechanism of action of 5-FU is inhibition of TS, which catalyzes a crucial rate-limiting step in DNA synthesis ([@b25-mco-0-0-1623]).

Several studies on metastatic CRC have demonstrated that high intratumoral TS levels are correlated with resistance to fluoropyrimidine treatment ([@b26-mco-0-0-1623]--[@b28-mco-0-0-1623]). Other studies have demonstrated that TS is a prognostic marker for patients with CRC ([@b29-mco-0-0-1623]) and metastatic CRC ([@b30-mco-0-0-1623]). Similar to the present study, Arienti *et al* demonstrated that TS expression is a marker of chemosensitivity of peritoneal carcinomatosis from colon cancer to 5-FU- and oxaliplatin-based chemotherapy ([@b31-mco-0-0-1623]). However, despite these promising results, TS has not been recommended for routine clinical practice as a predictor of response to 5-FU-based chemotherapy ([@b32-mco-0-0-1623]). Thus, the aim of the present study was to determine whether TS expression is a direct marker of the CRLM response to preoperative chemotherapy.

In this study, TS expression in the primary lesion, but not in CRLM, was identified as a predictive marker for the response to preoperative chemotherapy, as assessed by both TRG and RECIST. No significant difference in TS expression was found between the primary lesion and CRLM. Therefore, it appears that other molecular characteristics of the primary tumor must have been altered during the metastatic process ([@b33-mco-0-0-1623]). Chemotherapy may also have modified the tumor characteristics ([@b34-mco-0-0-1623]). We hypothesized that such factors may explain why TS expression in liver metastases was not a predictive marker of response.

ERCC1 expression was not found to be a predictive marker of response to preoperative chemotherapy. It was previously suggested that ERCC1 is a good predictive chemosensitivity marker for oxaliplatin-based chemotherapy ([@b11-mco-0-0-1623]); however, other studies have demonstrated that TS expression is a better predictive chemosensitivity marker compared with ERCC1 for 5-FU- and oxaliplatin-based chemotherapy ([@b28-mco-0-0-1623],[@b31-mco-0-0-1623],[@b35-mco-0-0-1623],[@b36-mco-0-0-1623]). In agreement with the latter reports, we found that TS expression is a more useful predictor of chemosensitivity to 5-FU- and oxaliplatin-based chemotherapy compared with ERCC1 expression. Although ERCC1 was a good predictive marker for oxaliplatin-based chemotherapy, previous reports included several factors, such as inclusion criteria, outcome and stage, and it remains controversial whether it is also a direct good predictive marker for response to 5-FU- and oxaliplatin-based chemotherapy.

There were certain limitations to the present study. First, this was a small, retrospective, non-randomized study, and the results may have been affected by its retrospective design. The inclusion or exclusion criteria for preoperative chemotherapy were not strictly defined. We included only patients who proceeded to receive surgery, whereas patients with CRLM who failed to convert to resectability were excluded. Thus, the patients with the lowest responses may have been excluded from this study.

Ideally, these problems could be overcome by performing liver biopsies before and after chemotherapy. However, liver biopsy is not practically recommended due to the risk of tumor spillage, which may be the cause of peritoneal carcinomatosis ([@b37-mco-0-0-1623]). For this reason, only specimens resected by surgery were evaluated. Second, we did not analyze prognosis in terms of disease-free survival and overall survival, mainly because prognosis was significantly affected by the postoperative treatment. Therefore, we considered that the chemotherapy response based on pathological and radiological assessments would allow for direct analysis of the association between protein expression and the tumor response to therapy.

In summary, the results of the present study demonstrated a significant association between TS expression in the primary colorectal tumor and response to preoperative chemotherapy as assessed by both TRG and RECIST. Although investigations of larger patient cohorts are required to confirm our results, the data of the present study suggest that TS expression in the primary lesion may be a predictive marker for the response of CRLM to 5-FU- and oxaliplatin-based preoperative chemotherapy.
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###### 

Patient characteristics (n=24).

  Characteristics                              No.
  -------------------------------------------- -------------------
  Age, years (median, range)                   64 (39--78)
  Sex, male/female                             16/8
  Tumor classification of the primary lesion   
    T2/T3/T4                                   1/14/9
  Node classification                          
    N0/N1/N2/N3                                7/8/6/3
  Differentiation                              
    Tub1/Tub2/muc                              7/16/1
  Location                                     
    Colon/rectum                               15/9
  Number of metastases                         
    Multiple/solitary                          19/5
  Grade of liver metastases                    
    H1/H2/H3                                   8/11/5
  Size of largest metastasis prior to          51.4 (7.8--130.9)
  chemotherapy, mm (median, range)             
  Size of largest metastasis after             34.2 (9--91.8)
  chemotherapy, mm (median, range)             
  No. of chemotherapy cycles (median, range)   6 (3--56)
  Chemotherapy regimen                         
    FOLFOX/XELOX                               21/3
  Molecular targeted drug                      
    P-mab/C-mab/Bev                            8/1/11
  Response Evaluation Criteria in Solid        
  Tumors (RECIST)                              
    CR/PR/SD/PD                                0/17/5/2
  Tumor Regression Grade (TRG)                 
    1/2/3/4/5                                  2/13/4/4/1
  ERCC1 expression in primary lesion           
    Negative/positive                          9/14
  ERCC1 expression in liver metastasis         
    Negative/positive                          15/9
  TS expression in primary lesion              
    Negative/positive                          12/11
  TS expression in liver metastasis            
    Negative/positive                          18/6

Tub1, well differentiated; tub2, moderately differentiated; muc, mucinous; FOLFOX, 5-fluorouracil, folinic acid and oxaliplatin; XELOX, capecitabine and oxaliplatin; P-mab, panitumumab; C-mab, cetuximab; Bev, bevacizumab; CR, complete response; PR, partial response; SD, stable disease; PD, progressive disease; ERCC1, excision repair cross-complementation group 1; TS, thymidylate synthase.

###### 

Correlation between response based on TRG and RECIST.

                  Response according to RECIST       
  --------------- ------------------------------ --- --------
  TRG1-3 (n=19)   17                             2   0.0005
  TRG4-5 (n=5)    0                              5   

TRG, Tumor Regression Grade; RECIST, Response Evaluation Criteria In Solid Tumors; PD, progressive disease; PR, partial response; SD, stable disease; TRG1-3, responder; TRG4-5, non-responder.

###### 

Response to preoperative chemotherapy based on RECIST.

  Variables                                                      PR (n=17)            SD + PD (n=7)      P-value
  -------------------------------------------------------------- -------------------- ------------------ ---------
  Age, years (median, range)                                     63 (39--78)          71 (41--75)        0.2151
  Sex                                                                                                    
    Male                                                         13                   3                  0.1670
    Female                                                       4                    4                  
  Tumor classification of the primary lesion                                                             
    T1, T2                                                       1                    0                  1.000
    T3, T4                                                       16                   7                  
  Node classification                                                                                    
    N0                                                           4                    3                  0.3742
    N1, N2                                                       13                   4                  
  Location                                                                                               
    Colon                                                        11                   4                  1.000
    Rectum                                                       6                    3                  
  Number of metastases                                                                                   
    Solitary                                                     2                    3                  0.1265
    Multiple                                                     15                   4                  
  Size of metastases prior to chemotherapy, mm (median, range)   63.2 (17.2--130.9)   33.6 (7.8--87.8)   0.0454
  Molecular targeted drug                                                                                
    P-mab, C-mab                                                 8                    1                  0.0847
    Bev                                                          8                    3                  
    None                                                         1                    3                  
  TS expression in primary lesion                                                                        
    Negative                                                     11                   1                  0.0272
    Positive                                                     5                    6                  
  TS expression in liver metastasis                                                                      
    Negative                                                     13                   5                  1.000
    Positive                                                     4                    2                  
  ERCC1 expression in primary lesion                                                                     
    Negative                                                     6                    3                  1.000
    Positive                                                     10                   4                  
  ERCC1 expression in liver metastasis                                                                   
    Negative                                                     11                   4                  1.000
    Positive                                                     6                    3                  

RECIST, Response Evaluation Criteria in Solid Tumors; tub1, well differentiated; tub2, moderately differentiated; muc, mucinous; FOLFOX, 5-flurouracil, folinic acid and oxaliplatin; XELOX, capecitabine and oxaliplatin; P-mab, panitumumab; C-mab, cetuximab; Bev, bevacizumab; PR, partial response; SD, stable disease; PD, progressive disease; ERCC1, excision repair cross-complementation group 1; TS, thymidylate synthase.

###### 

Response to preoperative chemotherapy based on TRG.

  Variables                                                    TRG1-3 (n=19)       TRG4-5 (n=5)       P-value
  ------------------------------------------------------------ ------------------- ------------------ ---------
  Age, years (median, range)                                   63 (39--78)         71 (42--74)        0.4339
  Sex                                                                                                 
    Male                                                       14                  2                  0.2885
    Female                                                     5                   3                  
  Tumor classification of the primary lesion                                                          
    T1, T2                                                     1                   0                  1.000
    T3, T4                                                     18                  5                  
  Node classification                                                                                 
    N0                                                         5                   2                  0.6080
    N1, N2                                                     14                  3                  
  Location                                                                                            
    Colon                                                      11                  4                  0.6146
    Rectum                                                     8                   1                  
  Number of metastases                                                                                
    Solitary                                                   4                   1                  1.000
    Multiple                                                   15                  4                  
  Size of metastases before chemotherapy, mm (median, range)   56.2 (17.2--30.9)   18.4 (7.8--87.8)   0.0699
  Molecular targeted drug                                                                             
    P-mab, C-mab                                               8                   1                  0.3385
    Bev                                                        9                   2                  
    None                                                       2                   2                  
  TS expression in primary lesion                                                                     
    Negative                                                   12                  0                  0.0137
    Positive                                                   6                   5                  
  TS expression in liver metastasis                                                                   
    Negative                                                   12                  3                  1.000
    Positive                                                   7                   2                  
  ERCC1 expression in primary lesion                                                                  
    Negative                                                   8                   1                  0.6106
    Positive                                                   10                  4                  
  ERCC1 expression in liver metastasis                                                                
    Negative                                                   14                  4                  1.000
    Positive                                                   5                   1                  

TRG, Tumor Regression Grade; tub1, well differentiated; tub2, moderately differentiated; muc, mucinous; FOLFOX, 5-fluorouracil, folinic acid and oxaliplatin; XELOX, capecitabine and oxaliplatin; P-mab, panitumumab; C-mab, cetuximab; Bev, bevacizumab; PR, partial response; SD, stable disease; PD, progressive disease; ERCC1, excision repair cross-complementation group 1; TS, thymidylate synthase.

###### 

Correlation between TS and ERCC1 expression in matched pairs of primary lesions and CRLM.

                                       TS expression in CRLM                 
  ------------------------------------ -------------------------- ---------- ---------
  TS expression in primary lesion                                            0.371
    Negative                           10                         2          
    Positive                           7                          4          
                                                                             
                                       ERCC1 expression in CRLM              
                                                                             
                                       Negative                   Positive   P-value
                                                                             
  ERCC1 expression in primary lesion                                         1.00
    Negative                           6                          3          
    Positive                           8                          6          

TS, thymidylate synthase; ERCC1, excision repair cross-complementation group 1; CRLM, colorectal liver metastasis.
